Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New glasses lenses aim to stop kids from becoming nearsighted

NCT ID NCT07535658

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether special glasses lenses can prevent nearsightedness (myopia) in children aged 6 to 8 who are not yet nearsighted. About 255 children will wear either a new type of lens or a standard lens for at least 8 hours a day for one year. Researchers will check their eyes every 3 months to see if the lenses slow down changes that lead to myopia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 255 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 8 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 6 years ≤ age ≤ 8 years (calculated based on the informed consent date); 2. The spherical equivalent (SE) of both eyes is 0D to +1.00D (inclusive of boundary values) after cycloplegia; 3. Astigmatism: Cylindrical power of both eyes ≤ 1.00D; 4. Anisometropia: Difference in spherical equivalent between both eyes ≤ 1.00D; 5. Corrected visual acuity: Best corrected visual acuity (BCVA) of both eyes ≥ 1.0 (decimal notation, 5m); 6. General health status: No systemic syndromes that affect ocular development; no long-term use of growth hormone, corticosteroids, or antiepileptic drugs; 7. Previous intervention: No use of any myopia control methods within the past 3 months, including but not limited to: multifocal glasses, atropine eye drops, red light therapy, acupuncture, etc. 8. Compliance with spectacle wear: Parents ensure that the child wears glasses for ≥8 hours per day; 9. Follow-up capability: Ability to attend scheduled follow-ups for 12 months (4 visits in total); 10. Informed consent from guardian: Legal guardian signs the informed consent form; children also sign the assent form. Exclusion Criteria: 1. History or presence of glaucoma, corneal disease, or other ocular organic disease, or acute or chronic ocular inflammation; 2. Combined with systemic major diseases, mental diseases, or systemic collagen metabolism diseases; 3. Used any myopia intervention drugs or devices in the past 3 months; 4. Those who have participated in other similar clinical studies in the past 3 months; 5. Diagnosis of amblyopia, constant strabismus, and other congenital eye diseases; 6. Those who are allergic to the lens material or products related to the study; 7. Allergy to mydriatic agents and related ophthalmic medications; 8. Allergic to photochromic materials or related dyes; taking photosensitizing drugs; suffering from photo-induced skin or neurological disorders; 9. Unable to understand the study content or unable to cooperate with the follow-up; 10. Other reasons why the research doctor believes the patient is not suitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Eye Disease Prevention and treatment Center

    Shanghai, 200336, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.